Implementation of accelerated clinical pathways based on the fast-track principles reduces morbidity and enhances recovery for patients undergoing THA ([Kehlet and Wilmore 2008](#C10){ref-type="ref"}). One of the key prerequisites is optimized pain relief, allowing early postoperative mobilization ([Kehlet and Wilmore 2008](#C10){ref-type="ref"}). This requires that the pain treatment should be safe and effective, both at rest and during activity ([Srikandarajah and Gilron 2011](#C22){ref-type="ref"}).

The concept of multimodal analgesia for acute postoperative pain is to combine analgesics with additive or synergistic effects, which is meant to reduce the use of---and the adverse effects of---opioids and to allow early mobilization ([Kehlet and Dahl 1993](#C9){ref-type="ref"}, [Kehlet et al. 1999](#C11){ref-type="ref"}, [Buvanendran and Kroin 2009](#C4){ref-type="ref"}). Multimodal analgesia in THA usually includes analgesics such as opioids, gabapentin, NSAIDs, acetaminophen, glucocorticoids, and local infiltration ([Kardash et al. 2008](#C8){ref-type="ref"}, [Kerr and Kohan 2008](#C12){ref-type="ref"}, [Toms et al. 2008](#C23){ref-type="ref"}, [Fredheim et al. 2011](#C6){ref-type="ref"}, [Maund et al. 2011](#C16){ref-type="ref"}, [Zhang et al. 2011](#C26){ref-type="ref"}).

[Kerr and Kohan (2008)](#C12){ref-type="ref"} reported reduced opioid requirements and reduced hospital stay with the use of LIA consisting of ropivacaine and NSAIDs. However, trials investigating the effect of ropivacaine in LIA have not determined whether ropivacaine alone gives similar improvements following THA ([Lunn et al. 2011](#C15){ref-type="ref"}, [Dobie et al. 2012](#C5){ref-type="ref"}, [Zoric et al. 2014](#C27){ref-type="ref"}). Studies using LIA have often combined different analgesics ([Kerr and Kohan 2008](#C12){ref-type="ref"}, [Kuchalik et al. 2013](#C13){ref-type="ref"}), and this complicates interpretation of the results regarding the extent to which ropivacaine alone contributes to the outcome.

Various studies have shown that LIA does not provide any additional analgesic benefit or reduce opioid consumption after THA ([Lunn et al. 2011](#C15){ref-type="ref"}, [Dobie et al. 2012](#C5){ref-type="ref"}, [Solovyova et al. 2013](#C21){ref-type="ref"}, [Zoric et al. 2014](#C27){ref-type="ref"}), and some authors do not recommend LIA in addition to a multimodal analgesic regimen after THA ([Andersen et al. 2011](#C2){ref-type="ref"}, [Lunn et al. 2011](#C15){ref-type="ref"}). Other studies have shown that LIA reduces the opioid consumption ([Andersen et al. 2007](#C1){ref-type="ref"}, [Kerr and Kohan 2008](#C12){ref-type="ref"}, [Busch et al. 2010](#C3){ref-type="ref"}, [Murphy et al. 2012](#C17){ref-type="ref"}, [Kuchalik et al. 2013](#C13){ref-type="ref"}) and shortens the hospital stay after THA ([Kerr and Kohan 2008](#C12){ref-type="ref"}, [Scott et al. 2012](#C20){ref-type="ref"}) The results are thus conflicting, and the role of LIA in THA surgery still needs to be clarified.

We investigated whether a single-shot LIA with ropivacaine in addition to a multimodal analgesic regimen would reduce acute postoperative pain and opioid requirements after THA.

Material and methods {#S0001}
====================

Patients {#S0002}
--------

Patients scheduled for elective primary THA in the orthopedic outpatient clinic of St. Olav's Hospital in Trondheim were screened for inclusion in this study from March 2013 through March 2014. Preoperatively, the patients attended a patient educational seminar. All patients were included regardless of age, ASA score, or type of prosthesis. THA was performed with a standard direct lateral approach.

Exclusion criteria were contraindications to receive spinal anesthesia, dexamethasone, or acetaminophen. Patients who received general anesthesia and patients who were operated with an approach different to standard direct lateral one were excluded. Patients with osteosynthesis to be removed at the same operation were also excluded from this study.

116 patients were included in the study. [Figure 1](#F1){ref-type="fig"} shows the flow of patients through the study, and the demographic data and baseline data are presented in [Table 1](#TB1){ref-type="table"}.

![CONSORT 2011 flow chart of patients throughout the study.](iort-86-654.01){#F1}

###### 

Baseline demographic of study patients

  Placebo (n = 54)               Ropivacain (n = 55)   
  ------------------------------ --------------------- ----------------
  Age                            65 (24--88)           66 (49--85)
  Sex: F / M                     36 / 18               40 / 15
  ASA: 1 / 2 / 3 / 4             11 / 33 / 9 / 1       8 / 40 / 7 / 0
  Smoking                                              
   Never                         47                    46
   Sometimes                     5                     2
   Daily                         2                     7
  BMI                            27 (20--39)           26 (20--41)
  Time of surgery, min           70 (42--123)          74 (45--122)
  Charnley class                 1 (1--3)              1.5 (1--3)
  NRS mobilized preoperatively   5.5 (2--10)           6 (2--10)

Data are mean or median (range) where appropriate.

Randomization and blinding {#S0003}
--------------------------

This was a randomized, double-blind, placebo-controlled trial.The patients were randomized to receive either LIA or placebo. Randomization was done by the unit of Clinical Health Science at NTNU in Trondheim. Numbered, sealed envelopes were opened by the operating nurse on the day of surgery. The surgeon, the anesthesia personnel, the nursing staff, and the patients were all blind regarding patient allocation throughout the study.

Study intervention {#S0004}
------------------

All patients got a premedication cocktail consisting of dexamethasone (16--20 mg), etoricoxib (90 mg) and acetaminophen (1.5--2 g).

All patients were operated under spinal anesthesia with 2.0--3.0 mL bupivacaine, 0.5% plain, preferably at the L2/L3 or the L3/L4 vertebral interspace. Propofol infusion was administered for sedation if required. A standardized program for intraoperative fluid administration was followed, consisting of 1--1.5 L Ringer's acetate, tranexamic acid (15 mg/kg, max. 1.5 g), and cephalothin (2 g).

The patients were randomized to receive either LIA or placebo. The LIA consisted of 150 mL ropivacaine (2 mg/mL) and 0.5 mL epinephrine (1 mg/mL), not including ketorolac, as described by [Kerr and Kohan (2008)](#C12){ref-type="ref"}. The other group received 150 mL 0.9% saline.

The solution was prepared in 3 unmarked 50-mL syringes by the operating nurse before the patient, the anesthetic personnel, and the surgeon arrived at the operating room.

Local infiltration analgesia or placebo was injected by the surgeon in a standardized manner ([Kerr and Kohan 2008](#C12){ref-type="ref"}). The first 50 mL was injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 mL was inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 mL was inserted in the subcutaneous layers.

The patients followed the standardized fast-track clinical pathway for hip and knee arthroplasty at Trondheim University Hospital ([Winther et al. 2014](#C25){ref-type="ref"}), and they were mobilized in the post-anesthesia care unit (PACU) as soon as the effect of the spinal anesthetic had worn off. At the PACU, morphine was given intravenously if required when the patients needed extra pain-reducing medicine.

Thereafter, the patients were transferred to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation. Multimodal orally administered opioid-sparing analgesia was given to all the patients; NSAIDS and acetaminophen were given at regular intervals and oxycodone was given if needed.

Study parameters {#S0005}
----------------

The primary endpoint in this study was pain sensation during mobilization in the PACU. The secondary endpoint was pain during mobilization on the day after surgery and total consumption of opioids on the first postoperative day.

Pain was registered using the numeric rating scale (NRS), by the nurses in the PACU and in the hip arthroplasty ward unit. The patients were asked a standard question: "On a scale from 0 to 10, where 0 is no pain and 10 is the worst imaginable pain, can you define the pain you have right now?"

Mobilization in the PACU consisted of sitting at the bed, and standing and walking a few steps at the bedside with assistance from the nurse. In addition, the patients were given physiotherapy in the hip arthroplasty ward unit.

Pain score was also examined at rest. In addition, the use of opioids, the number of hours mobilized, and the length of hospital stay were registered.

Statistics {#S0006}
----------

The estimated sample size was based on pain score during mobilization in the PACU. With a mean pain score of 2.1 and an SD of 1.8 (known from our own registry data), a level of significance of 0.05%, and a power of 80%, a 1-point difference in NRS would be detected with 52 patients in each group.

The continuous numeric variables for pain scores and opioid consumption were tested for normality of distribution with the Kolmogorov-Smirnov test, histogram and QQ-plot.

The 2 groups were compared with the Mann-Whitney U-test, as the data were not normally distributed. Pain score and total consumption of opioids are therefore presented as median with interquartile range.

Both morphine and ketobemidone were given to the patients in the PACU. These opioids are considered to be equipotent ([Rygnestad and Slordal 2000](#C19){ref-type="ref"}), and they were merged when the total consumption of opioids was calculated.

All statistical analyses were conducted with IBM SPSS version 21.

Ethics and registration {#S0007}
-----------------------

Written and verbal informed consent was obtained from each patient before inclusion in the study, and the study was conducted in accordance with the Declaration of Helsinki. The project was approved by the regional committees for medical and health research ethics (2012/1999). The study was registered at ClinicalTrials.gov (identifier NCT02359136).

Results {#S0008}
=======

The median pain score during mobilization in the PACU was 3 in boths groups (p = 0.7). The median pain score during mobilization on the first postoperative day was 4 in both groups (p = 0.3) ([Figure 2](#F2){ref-type="fig"}).

![Box plot showing pain score (NRS) during mobilization in the post-anesthesia care unit (PACU) and on the first postoperative day. The horizontal lines indicate median. The boxes represent interquartile range and the whiskers extend to the minimum or maximum case/value within 1.5 times the height of the boxes.](iort-86-654.02){#F2}

Median opioid consumption in the PACU was 0 (0--3.1) mg and 0 (0--5) mg in the placebo and the ropivacaine group respectively (p = 0.9) ([Table 2](#TB2){ref-type="table"}).

###### 

Results

  Placebo                   Ropivacaine   p-value       
  ------------------------- ------------- ------------- -----
  NRS mobilized PACU        3 (2--4)      3 (0--4)      0.7
  NRS mobilized day 1       4 (3--5)      4 (3--5)      0.3
  NRS rest PACU             2 (1--3)      2 (0--3)      0.4
  NRS rest day 1            2 (1--3)      2 (1--3)      0.4
  Opioid use PACU, mg       0 (0--3.1)    0 (0--5)      0.9
  Oxycodone use day 1, mg   20 (10--30)   20 (10--30)   0.4
  Mobilized day 1, h        9 (7--12)     9 (6--11)     0.7
  LOS, days                 2 (2--3)      3 (2--3)      0.5

Data are median (interquartile range).

Total oxycodone consumption on the first postoperative day was 20 (10--30) mg in both groups (p = 0.3) ([Table 2](#TB2){ref-type="table"}).

Discussion {#S0009}
==========

We found that LIA with 0.2% ropivacaine does not provide any analgesic effect after THA in addition to a multimodal analgesic regimen consisting of spinal anesthesia, NSAID, acetaminophen, and glucocorticoid. There was no statistically significant increase in pain score or consumption of opioids during mobilization in the PACU or on the day after surgery.

The widespread LIA technique was described by [Kerr and Kohan (2008)](#C12){ref-type="ref"} to reduce opioid requirements and improve postoperative mobilization after THA. They added ketorolac to the ropivacaine and epinephrine mixture and the effect of LIA alone was therefore not studied. The authors found a low pain score---generally in the range of 0--3---both at rest and while walking, and reduced opioid consumption. Almost half of the patients were directly discharged home on the first postoperative day.

Using both NSAIDs and opioids in LIA is controversial, and few studies have attempted to identify which components in the mixture contribute to the outcome. Addition of NSAIDs to the LIA mixture without giving NSAIDs to the control group makes the results of the studies difficult to interpret ([Andersen et al. 2007](#C1){ref-type="ref"}, [Kerr and Kohan 2008](#C12){ref-type="ref"}, [Kuchalik et al. 2013](#C13){ref-type="ref"}, [Solovyova et al. 2013](#C21){ref-type="ref"}) as NSAIDs have both a systematic and a local anti-inflammatory effect ([Romsing et al. 2000](#C18){ref-type="ref"}). Instead of measuring the effect of the local infiltration analgesia, it may be the effect of NSAID(s) that is measured, which complicates the comparison between LIA and placebo.

Several trials investigating the effect of LIA following THA have used different pain treatment modalities such as spinal analgesic, epidural analgesic, or systematic analgesic. In addition, these are often used in combination with a LIA catheter placed intraoperatively giving repeated injections postoperatively ([Andersen et al. 2007](#C1){ref-type="ref"}, [Kerr and Kohan 2008](#C12){ref-type="ref"}, [Murphy et al. 2012](#C17){ref-type="ref"}, [Kuchalik et al. 2013](#C13){ref-type="ref"}, [Solovyova et al. 2013](#C21){ref-type="ref"}, [Zoric et al. 2014](#C27){ref-type="ref"}). This further complicates interpretation and comparison of the results. In the present study, the patients received a single-shot local infiltration analgesic with ropivacain and epinephrine. NSAID was given as a part of a multimodal pain regimen. This makes the results of our study valid, as the only difference between the 2 groups was whether ropivacaine was administered.

A recent study with a similar design also had results comparable to ours. [Lunn et al. (2011)](#C15){ref-type="ref"} reported that infiltration with a single dose of 150 mL 0.2% ropivacaine with epinephrine following THA did not reduce postoperative consumption of opioids or reduce postoperative pain ([Lunn et al. 2011](#C15){ref-type="ref"}). In this study, they used a multimodal analgesic approach consisting of acetaminophen, NSAID, and gabapentin rather than the glucocorticoid used in our study ([Lunn et al. 2011](#C15){ref-type="ref"}). Gabapentin has possible side effects such as dizziness and visual disturbances, and its use is debatable as part of a multimodal pain regimen following THA ([Zhang et al. 2011](#C26){ref-type="ref"}).

A single preoperative dose of dexamethasone is a proven long-acting prophylactic agent for nausea and vomiting, and improves postoperative pain and mobilization ([Kardash et al. 2008](#C8){ref-type="ref"}, [Lunn and Kehlet 2013](#C14){ref-type="ref"}). A single dose of dexamethasone has no known side effects either in the short term or long term, apart from increased blood glucose level on the first postoperative day ([Waldron et al. 2013](#C24){ref-type="ref"}). There are no general recommendations for use of glucocorticoids following THA, and this suggests that further investigation is still required regarding dose-response and potential side effects.

Pain evoked by movement is often neglected as the primary clinical outcome following THA ([Srikandarajah and Gilron 2011](#C22){ref-type="ref"}). The fast-track methodology requires a procedure-specific pain regimen to allow early mobilization, and thereby reduce the length of convalescence and morbidity ([Kehlet and Wilmore 2008](#C10){ref-type="ref"}). In the present study, the patients had low postoperative pain scores irrespective of which study group they belonged to, both at rest and during mobilization. This indicates that the multimodal pain regimen that we used was safe, simple, and satisfactory---and that the patient's preoperative expectations were met through information and education ([Hamilton et al. 2013](#C7){ref-type="ref"}).

Our findings may be limited by missing registration of pain scores for 15 study participants during mobilization in the PACU, i.e. the primary outcome of this study. Nevertheless, this was a randomized trial, and we consider that the number of patients registered had a sufficient response rate to give reliable results.

One strength of our study was that the patients allocated to this trial were unselected. Our findings can therefore be generalized to other populations when using a multimodal pain regimen like ours after THA.

In conclusion, local infiltration analgesic with ropivacaine did not provide any extra analgesic effect after THA over and above that from the multimodal analgesic regimen consisting of acetaminophen, NSAID, and glucocorticoid.
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